Asia-Pacific epilepsy therapeutics market continues to grow as new drugs emerge
The epilepsy therapeutics market value in the Asia-Pacific (APAC) region - Australia, China, India and Japan - is expected to increase moderately, climbing from $1.1 billion in 2012 to $1.5 billion by 2019, at a compound annual growth rate (CAGR) of 4.7%.
According to business intelligence provider GBI Research latest report* China and India are expected to show the fastest growth over the forecast period, with CAGRs of 6.1% and 4.2%, respectively. Meanwhile, Australia and Japan will witness slightly lower CAGRs of 3.9% and 1.7%.
Vijaya Vulapalli, senior analyst for GBI Research, says: “With a high epilepsy prevalence, China and India have large treatment populations, which are expected to increase further in the future due to better healthcare access and an improvement in treatment gaps.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze